<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409873</url>
  </required_header>
  <id_info>
    <org_study_id>20-30874</org_study_id>
    <secondary_id>R00RG2901</secondary_id>
    <nct_id>NCT04409873</nct_id>
  </id_info>
  <brief_title>Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)</brief_title>
  <acronym>AMPoL</acronym>
  <official_title>Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5
      groups: distilled water, CloSYS (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B,
      USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine (Johnson and Johnson,
      USA).

      Study participants will be asked to rinse/gargle with 10ml (2 teaspoons) of the assigned
      solutions 4 times per day, for 30 seconds, for 4 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2, the virus causing COVID-19, has affected vulnerable individuals, especially those
      with comorbidities, and high exposure health care workers (HCWs). Typically, the virus first
      colonizes in the upper respiratory tract (URT) causing clinical symptoms such as coughing,
      sore throat, and then is transferred to the lower respiratory tract (LRT) which can lead to
      severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and death, if it is not
      managed.

      The World Health Organization (WHO) has presented comprehensive guidelines underscoring
      personal hygiene measures including respiratory hygiene against SARS, MERS, influenza, and
      now SARS-CoV-2 / COVID-19. While personal protection equipment (PPE), personal hygiene
      measures, environmental infection control, and physical distancing are crucial in mitigating
      disease transmission, respiratory hygiene measures do not prevent SARS-CoV-2 colonization in
      URTs and LRTs of infected individuals (symptomatic and asymptomatic).

      Experimental and clinical research studies on infections similar to COVID-19 such as SARS,
      MERS, and H5N1 have shown that using antiseptic mouthwash/gargling solutions, such as
      products containing chlorhexidine gluconate (CHG), polyvinylpyrrolidone iodine (PVP-I),
      chlorine dioxide (ClO2), cetylpyridinium chloride (CPC), and hydrogen peroxide (H2O2) can
      reduce viral load. A randomized controlled trial (N=387) showed efficacy and
      cost-effectiveness of gargling with water or a product containing PVP-I (3X/day, 20 seconds)
      on URTIs in healthy volunteers (18-65 years) over 60 days from a societal perspective; in
      vitro studies have shown that CloSYS, an over the counter mouthwash containing ClO2, was
      effective on inactivating SARS-CoV as well as disinfecting infected surfaces, dental unit
      waterlines, and biofilms in ultrasonic dental scaling units. Recently, the US Centers for
      Disease Control (CDC) and the American Dental Association (ADA) have recommended using a
      mouthwash containing 1.0-1.5% H2O2 as a pre-procedural rinse before dental treatment to
      potentially reduce SARS-CoV-2 load; however, no in vivo clinical studies have been conducted
      to support this claim.

      The aim of this pilot trial is to evaluate the effect of three over the counter antiseptic
      mouthwash/gargling solutions compared to a control (distilled water) to reduce SARS-CoV-2
      load. In addition, study participants will be assessed for the severity of their clinical
      symptoms during the study period. The 4-week protocol was selected as studies have shown that
      patients can continue to shed the virus and potentially transmit to the others for a 2 to 4
      week period. An interim analysis is planned when 10 participants per arm (50 total) complete
      the study using the alpha-spending function with O'Brien-Fleming boundary rule.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A blinded randomized controlled parallel group design trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Study participants will be blinded to the solutions to the extent possible (i.e., similar packages with identification number bar codes).
The lab technician who evaluates the SARS-CoV-2 load in samples will be blinded to the solutions and study groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SARS-Cov-2 viral load</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in saliva wash RT-PCR SARS-Cov-2 viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported clinical symptom onset</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in self-reported (questionnaire) clinical symptom onset. A symptom checklist will include: cough, runny nose, scratchy/sore throat, fever, chills, fatigue, muscle ache, shortness of breath, diarrhea/nausea/vomiting, loss of taste/smell, and red /painful eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in healthcare utilization and hospitalization</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in healthcare utilization and hospitalization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in SARS-Cov-2 viral load in tobacco users, marijuana smokers, or vapers</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in saliva wash RT-PCR SARS-Cov-2 viral load in tobacco users, marijuana smokers, or vapers</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in self-reported clinical symptom onset in tobacco users, marijuana smokers, or vapers</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in self-reported (questionnaire) clinical symptom onset in tobacco users, marijuana smokers, or vapers. A symptom checklist will include: cough, runny nose, scratchy/sore throat, fever, chills, fatigue, muscle ache, shortness of breath, diarrhea/nausea/vomiting, loss of taste/smell, and red /painful eye.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in healthcare utilization and hospitalization in tobacco users, marijuana smokers, or vapers</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in healthcare utilization and hospitalization in tobacco users, marijuana smokers, or vapers</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <condition>Virus Disease</condition>
  <condition>Coronavirus Infections</condition>
  <condition>Pharyngeal Diseases</condition>
  <arm_group>
    <arm_group_label>Control (Distilled Water)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Over the counter: Distilled water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral-B Mouth Sore (H2O2) mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CloSYS (ClO2) mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the counter: CloSYS (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Listerine Mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the counter: Listerine (Zero Alcohol)(Johnson and Johnson, USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral-B Mouth Sore mouthwash</intervention_name>
    <description>Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.</description>
    <arm_group_label>Oral-B Mouth Sore (H2O2) mouthwash</arm_group_label>
    <other_name>hydrogen peroxide</other_name>
    <other_name>H2O2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crest Pro-Health Multi-Protection mouthwash</intervention_name>
    <description>Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.</description>
    <arm_group_label>Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash</arm_group_label>
    <other_name>cetylpyridinium chloride</other_name>
    <other_name>C21H38ClN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CloSYS mouthwash</intervention_name>
    <description>Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.</description>
    <arm_group_label>CloSYS (ClO2) mouthwash</arm_group_label>
    <other_name>chlorine dioxide</other_name>
    <other_name>ClO2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Distilled water</intervention_name>
    <description>Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.</description>
    <arm_group_label>Control (Distilled Water)</arm_group_label>
    <other_name>water</other_name>
    <other_name>H2O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Listerine Mouthwash Product</intervention_name>
    <description>Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.</description>
    <arm_group_label>Listerine Mouthwash</arm_group_label>
    <other_name>Zero alcohol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tested positive for COVID-19 in prior 7 days

          -  Ability to read and speak in English

          -  Ability to participate in the study for 4 weeks

          -  Ability to gargle

          -  Not having any condition that might worsen with gargling solutions

          -  Not having an allergy to a study mouthwash ingredient

          -  Not using another mouthwash/gargling solution

          -  Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including
             off-label FDA-approved medications such as hydroxychloroquine)

          -  Anticipated ability to participate in the study for 4 weeks

          -  Have a cellphone and agree to receive text messages for reminders to use mouthwash
             during the day and for follow-up visits

        Exclusion Criteria:

          -  People who because of their symptoms intend to receive antiviral medications that
             could potentially affect viral load in their saliva samples

          -  Pregnant or lactating women due to potential aversions to mouthwash solution
             taste/smell.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart A Gansky, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Lee Hysan Chair of Oral Epidemiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stuart A Gansky, DrPH</last_name>
    <phone>415-502-8094</phone>
    <email>stuart.gansky@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sepideh Banava, DDS, MPH</last_name>
    <phone>415-855-1077</phone>
    <email>sepideh.banava@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stuart A Gansky, DrPH</last_name>
      <phone>415-502-8094</phone>
      <email>stuart.gansky@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sepideh Banava, DDS, MPH</last_name>
      <phone>415-855-1077</phone>
      <email>sepideh.banava@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart A Gansky, DrPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sepideh Banava, DDS, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://success.ada.org/en/practice-management/patients/coronavirus-frequently-asked-questions</url>
    <description>ADA Dental Practice Management Recommendations</description>
  </link>
  <link>
    <url>http://www.who.int/csr/bioriskreduction/infection_control/publication/en/.</url>
    <description>World Health Organization. Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care: WHO guidelines</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html#AdministrativeControls</url>
    <description>US Centers for Disease Control. Guidance for Dental Settings - Interim Infection Prevention and Control Guidance for Dental Settings During the COVID-19 Response: Administrative Controls and Work Practices. May 19, 2020</description>
  </link>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. J Dent Res. 2020 May;99(5):481-487. doi: 10.1177/0022034520914246. Epub 2020 Mar 12.</citation>
    <PMID>32162995</PMID>
  </reference>
  <reference>
    <citation>Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res. 2020 Jul;99(8):989. doi: 10.1177/0022034520918518. Epub 2020 Apr 9.</citation>
    <PMID>32271653</PMID>
  </reference>
  <reference>
    <citation>Reimer K, Wichelhaus TA, Schäfer V, Rudolph P, Kramer A, Wutzler P, Ganzer D, Fleischer W. Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology. 2002;204 Suppl 1:114-20.</citation>
    <PMID>12011534</PMID>
  </reference>
  <reference>
    <citation>Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology. 2002;204 Suppl 1:32-6.</citation>
    <PMID>12011518</PMID>
  </reference>
  <reference>
    <citation>Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther. 2018 Jun;7(2):249-259. doi: 10.1007/s40121-018-0200-7. Epub 2018 Apr 9.</citation>
    <PMID>29633177</PMID>
  </reference>
  <reference>
    <citation>Sakai M, Shimbo T, Omata K, Takahashi Y, Satomura K, Kitamura T, Kawamura T, Baba H, Yoshihara M, Itoh H; Great Cold Investigators-I. Cost-effectiveness of gargling for the prevention of upper respiratory tract infections. BMC Health Serv Res. 2008 Dec 16;8:258. doi: 10.1186/1472-6963-8-258.</citation>
    <PMID>19087312</PMID>
  </reference>
  <reference>
    <citation>Wang WK, Chen SY, Liu IJ, Chen YC, Chen HL, Yang CF, Chen PJ, Yeh SH, Kao CL, Huang LM, Hsueh PR, Wang JT, Sheng WH, Fang CT, Hung CC, Hsieh SM, Su CP, Chiang WC, Yang JY, Lin JH, Hsieh SC, Hu HP, Chiang YP, Wang JT, Yang PC, Chang SC; SARS Research Group of the National Taiwan University/National Taiwan University Hospital. Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis. 2004 Jul;10(7):1213-9.</citation>
    <PMID>15324540</PMID>
  </reference>
  <reference>
    <citation>Watamoto T, Egusa H, Sawase T, Yatani H. Clinical evaluation of chlorine dioxide for disinfection of dental instruments. Int J Prosthodont. 2013 Nov-Dec;26(6):541-4. doi: 10.11607/ijp.3465.</citation>
    <PMID>24179967</PMID>
  </reference>
  <reference>
    <citation>Wirthlin MR, Choi JH, Kye SB. Use of chlorine dioxide mouthrinse as the ultrasonic scaling lavage reduces the viable bacteria in the generated aerosols. J West Soc Periodontol Periodontal Abstr. 2006;54(2):35-44.</citation>
    <PMID>17214015</PMID>
  </reference>
  <reference>
    <citation>Chen C, Zhang XJ, Wang Y, Zhu LX, Liu J. Waste water disinfection during SARS epidemic for microbiological and toxicological control. Biomed Environ Sci. 2006 Jun;19(3):173-8.</citation>
    <PMID>16944772</PMID>
  </reference>
  <reference>
    <citation>Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020 Mar 3;12(1):9. doi: 10.1038/s41368-020-0075-9. Review.</citation>
    <PMID>32127517</PMID>
  </reference>
  <reference>
    <citation>Meister TL, Brüggemann Y, Todt D, Conzelmann C, Müller JA, Groß R, Münch J, Krawczyk A, Steinmann J, Steinmann J, Pfaender S, Steinmann E. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2020 Sep 14;222(8):1289-1292. doi: 10.1093/infdis/jiaa471.</citation>
    <PMID>32726430</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Infective Agents, Local</keyword>
  <keyword>Mouthwashes</keyword>
  <keyword>Gargle</keyword>
  <keyword>Saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pharyngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrogen Peroxide</mesh_term>
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Cetylpyridinium</mesh_term>
    <mesh_term>Chlorine dioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

